Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : Nature Pub. Group
    • Subject Terms:
    • Abstract:
      The teratogenic potential of valproate in pregnancy is well established; however, evidence regarding the long-term safety of other antiseizure medications (ASMs) during pregnancy remains limited. Using routinely collected primary care data from the UK and nationwide Swedish registries to create a cohort of 3,182,773 children, of which 17,495 were exposed to ASMs in pregnancy, we show that those exposed to valproate were more likely to receive a diagnosis of autism, intellectual disability, and ADHD, when compared to children not exposed to ASMs. Additionally, children exposed to topiramate were 2.5 times more likely to be diagnosed with intellectual disability (95% CI: 1.23-4.98), and those exposed to carbamazepine were 1.25 times more likely to be diagnosed with autism (95% CI: 1.05-1.48) and 1.30 times more likely to be diagnosed with intellectual disability (95% CI: 1.01-1.69). There was little evidence that children exposed to lamotrigine in pregnancy were more likely to receive neurodevelopmental diagnoses. While further research is needed, these findings may support considering safer treatment alternatives well before conception when clinically appropriate.
      Competing Interests: Competing interests T.T. has received support to the EURAP pregnancy registry from Accord, Eisai, GSK, UCB, Bial, Sanofi, GW Pharma, Teva, Angelini Pharma, Zentiva, SF Group, Glenmark and personal fees from Eisai, Sanofi, UCB and Angelini Pharma outside the submitted work. BL reports receiving consulting fees from Beasley Allen Law Firm, Patterson Belknap Webb & Tyler LLP and AlphaSights. None of the above entities had any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The remaining authors have no conflicts of interest.
      (© 2024. The Author(s).)
    • References:
      J Child Psychol Psychiatry. 2022 Jun;63(6):674-682. (PMID: 34414570)
      Seizure. 2023 Feb;105:56-64. (PMID: 36731257)
      N Engl J Med. 2009 Apr 16;360(16):1597-605. (PMID: 19369666)
      Lancet Neurol. 2013 Mar;12(3):244-52. (PMID: 23352199)
      Int J Epidemiol. 2024 Feb 1;53(1):. (PMID: 38124510)
      Acta Psychiatr Scand. 2006 Oct;114(4):257-64. (PMID: 16968363)
      Int J Epidemiol. 2015 Feb;44(1):345-54. (PMID: 25604449)
      Neurology. 2020 Dec 15;95(24):e3232-e3240. (PMID: 33115775)
      JAMA. 2013 Apr 24;309(16):1696-703. (PMID: 23613074)
      Gen Psychiatr. 2024 Jan 30;37(1):e101201. (PMID: 39228867)
      Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):923-933. (PMID: 31197928)
      Eur J Epidemiol. 2009;24(11):659-67. (PMID: 19504049)
      JAMA Psychiatry. 2013 Nov;70(11):1224-30. (PMID: 24068245)
      N Engl J Med. 2024 Mar 21;390(12):1069-1079. (PMID: 38507750)
      JAMA Neurol. 2021 Aug 1;78(8):927-936. (PMID: 34096986)
      Epidemiology. 2020 Jan;31(1):75-81. (PMID: 31651661)
      BJOG. 2024 Jan;131(1):15-25. (PMID: 37340193)
      Children (Basel). 2022 Dec 24;10(1):. (PMID: 36670582)
      Sci Rep. 2020 Oct 22;10(1):17362. (PMID: 33093466)
      JAMA Neurol. 2022 Jul 1;79(7):672-681. (PMID: 35639399)
      Global Spine J. 2022 Sep;12(7):1624-1626. (PMID: 35723546)
      Epidemiology. 2020 Sep;31(5):636-643. (PMID: 32501812)
      Cochrane Database Syst Rev. 2014 Oct 30;(10):CD010236. (PMID: 25354543)
      Biostatistics. 2021 Jul 17;22(3):598-612. (PMID: 31804668)
      JAMA Neurol. 2023 Jun 1;80(6):568-577. (PMID: 37067807)
      JAMA Netw Open. 2020 Nov 2;3(11):e2025570. (PMID: 33170264)
      J Neurol Sci. 2008 Aug 15;271(1-2):1-14. (PMID: 18479711)
      J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):637-43. (PMID: 23370617)
      Eur J Epidemiol. 2023 Jan;38(1):109-120. (PMID: 36595114)
      JAMA. 2024 Apr 9;331(14):1205-1214. (PMID: 38592388)
      Stat Med. 2002 Aug 15;21(15):2175-97. (PMID: 12210632)
      Neurology. 2023 Feb 14;100(7):e728-e738. (PMID: 36323520)
      BMC Med Res Methodol. 2015 Apr 14;15:35. (PMID: 25880989)
      Drug Saf. 2017 May;40(5):387-397. (PMID: 28188601)
      Pharmacoepidemiol Drug Saf. 2023 Aug;32(8):886-897. (PMID: 36919941)
      Nat Commun. 2024 Nov 15;15(1):9640. (PMID: 39548057)
      Pract Neurol. 2018 Jun;18(3):176-178. (PMID: 29686038)
    • Grant Information:
      R01 NS107607 United States NS NINDS NIH HHS
    • Accession Number:
      0 (Anticonvulsants)
      614OI1Z5WI (Valproic Acid)
      33CM23913M (Carbamazepine)
      U3H27498KS (Lamotrigine)
      0H73WJJ391 (Topiramate)
    • Publication Date:
      Date Created: 20241115 Date Completed: 20241116 Latest Revision: 20241203
    • Publication Date:
      20241204
    • Accession Number:
      PMC11568279
    • Accession Number:
      10.1038/s41467-024-53813-1
    • Accession Number:
      39548057